In this Healio Video Perspective from the ASRS meeting, Christina Y. Weng, MD, MBA, FASRS, of Baylor College of Medicine in Houston discusses 96-week safety and tolerability data for aflibercept 8 mg.
According to Weng, the pooled safety analysis included 1,773 patients who received more than 10,000 injections over approximately 2 years and investigated aflibercept 8 mg vs. aflibercept 2 mg for the treatment of wet age-related macular degeneration and diabetic macular edema. Data were pooled through week 44 of the phase 2 CANDELA study and week 96 of the phase 3 PULSAR and PHOTON trials.
“Aflibercept